Evidence map›Paper›PMID 39429294›Full record

ArticleCureus2024

Optimizing Titanium Carbide-Silver Oxide Nanostructures for Targeted Cancer Therapy: Synthesis, Functionalization, and In Vitro Evaluations.

Dharshini B, Geetha A, Vasugi S, Balachandran S, Ilangovar I G K

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dharshini BDepartment of Physiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Geetha ADepartment of Physiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Vasugi SDepartment of Physiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Balachandran SDepartment of Physiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Ilangovar I G KDepartment of Physiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction  Cancer remains a significant health challenge, and nanoparticles (NPs) are promising candidates for cancer treatment due to their unique physicochemical properties and ability to selectively target tumour cells. Two-dimensional (2D) nanomaterials, such as MXenes, have attracted interest due to their electronic structures, optical properties, catalytic abilities, and exceptional physicochemical attributes. MXenes are highly suitable for surface functionalization or modification, and their unique properties make them promising candidates for various applications in the biological field. Silver-based compounds have shown remarkable potential in biomedical fields, with silver oxide (Ag₂O) NPs finding applications in various domains. The fabrication of titanium carbide (Ti₃C₂)-Ag₂O heterostructures has been investigated for their anti-cancer properties by conducting cell viability assays on different cell lines. Aim To synthesize and characterize Ti₃C₂-Ag₂O, and to assess its in vitro anti-cancer activity. Materials and methods Ti₃C₂ synthesis begins by dissolving Ti₃AlC₂ powder in a 50% v/v hydrofluoric (HF) acid solution, allowing the aluminium to be etched away. This process should be conducted with continuous stirring for 24 to 48 hours at ambient temperature. Following this, filter the resulting suspension to eliminate aluminium particles and HF, and subsequently wash the Ti₃C₂ MXene with distilled water until a neutral pH is attained. The MXene should then be dispersed in ethanol, and sonication in deionized (DI) water or an alternative solvent should be employed to achieve exfoliation into monolayer or few-layer MXenes. To prepare Ag₂O NPs, dissolve silver nitrate (AgNO₃) in DI water to create a 0.1 M solution, and concurrently prepare a separate 0.1 M sodium hydroxide (NaOH) solution. Introduce the NaOH solution to the AgNO₃ while stirring until a precipitate is observed. The mixture should then be filtered, washed with distilled water, and the NPs dried at 60°C for 12 hours. To fabricate the MXene-Ag₂O composite, disperse the MXene nanoflakes in a solvent through sonication, incorporate the Ag₂O NPs, and stir the mixture for 24 hours. Finally, centrifuge the resultant mixture to isolate the composite, wash it with solvent, and dry it under vacuum conditions. Results The presence of Ag₂O particles on Ti₃C₂ nanosheets was observed, and the high crystallinity of the compound was confirmed through X-ray diffraction (XRD), energy-dispersive spectroscopy (EDS), and scanning electron microscopy (SEM) analyses. These tests verified that the compound was free of impurities and exhibited anti-cancer properties. Conclusion  The synthesis of Ti₃C₂ MXenes and Ag₂O NPs was achieved and confirmed through structural characterization methods, including SEM, XRD, and EDS. SEM provided detailed insights into the morphology and distribution of the nanostructures, while XRD and EDS verified their phase purity and elemental composition. Functionalization strategies were employed to enhance the stability and bioactivity of the nanocomposites. In vitro evaluations demonstrated promising anti-cancer activity, indicating that the Ti₃C₂-Ag₂O composites effectively target and inhibit cancer cell growth.

Indexed as

anticancer activitycolorimetric assayin vitro evaluationmxenesilver oxide

Identifiers

PMID39429294
PMCPMC11491128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.